PIRRACCHIO, Romain, Jiří PAŘENICA, Matthieu Resche RIGON, Sylvie CHEVRET, Jindřich ŠPINAR, Jiří JARKOVSKÝ, Faiez ZANNAD, Francois ALLA and Alexandre MEBAZAA. The Effectiveness of Inodilators in Reducing Short Term Mortality among Patient with Severe Cardiogenic Shock: A Propensity-Based Analysis. Plos One. SAN FRANCISCO: PUBLIC LIBRARY SCIENCE, 2013, vol. 8, No 8, p. e71659, 10 pp. ISSN 1932-6203. Available from: https://dx.doi.org/10.1371/journal.pone.0071659.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The Effectiveness of Inodilators in Reducing Short Term Mortality among Patient with Severe Cardiogenic Shock: A Propensity-Based Analysis
Authors PIRRACCHIO, Romain (250 France), Jiří PAŘENICA (203 Czech Republic, guarantor, belonging to the institution), Matthieu Resche RIGON (250 France), Sylvie CHEVRET (250 France), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Faiez ZANNAD (250 France), Francois ALLA (250 France) and Alexandre MEBAZAA (250 France).
Edition Plos One, SAN FRANCISCO, PUBLIC LIBRARY SCIENCE, 2013, 1932-6203.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.534
RIV identification code RIV/00216224:14110/13:00069742
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1371/journal.pone.0071659
UT WoS 000323378000063
Keywords in English ACUTE HEART-FAILURE; MICROCIRCULATORY BLOOD-FLOW; VENTRICULAR-FUNCTION; CONTROLLED TRIAL; NOREPINEPHRINE; DOBUTAMINE; NITROGLYCERIN; EPINEPHRINE; GUIDELINES; MANAGEMENT
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 15/10/2013 16:46.
Abstract
Background:The best catecholamine regimen for cardiogenic shock has been poorly evaluated. When a vasopressor is required to treat patients with the most severe form of cardiogenic shock, whether inodilators should be added or whether inopressors can be used alone has not been established. The purpose of this study was to compare the impact of these two strategies on short-term mortality in patients with severe cardiogenic shocks.Methods and Results:Three observational cohorts of patients with decompensated heart failure were pooled to comprise a total of 1,272 patients with cardiogenic shocks. Of these 1,272 patients, 988 were considered to be severe because they required a vasopressor during the first 24 hours. We developed a propensity-score (PS) model to predict the individual probability of receiving one of the two regimens (inopressors alone or a combination) conditionally on baseline-measured covariates. The benefit of the treatment regimen on the mortality rate was estimated by fitting a weighted Cox regression model. A total of 643 patients (65.1%) died within the first 30 days (inopressors alone: 293 (72.0%); inopressors and inodilators: 350 (60.0%)). After PS weighting, we observed that the use of an inopressor plus an inodilator was associated with an improved short-term mortality (HR: 0.66 [0.55-0.80]) compared to inopressors alone.Conclusions:In the most severe forms of cardiogenic shock where a vasopressor is immediately required, adding an inodilator may improve short-term mortality. This result should be confirmed in a randomized, controlled trial.
PrintDisplayed: 30/7/2024 06:08